- Algernon Pharmaceuticals (AGN) has received requests from patients participating in its Phase 2 proof of concept study of NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis (IPF) and chronic cough
- The patients have requested an ongoing supply of Ifenprodil for their personal use beyond the study’s treatment period
- The company is helping the clinical sites obtain additional drug supply through the Australian Government’s Special Access Scheme
- Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications
- Algernon Pharmaceuticals Inc. (AGN) opened trading at C$4.29
Patients participating in Algernon Pharmaceuticals’ (AGN) clinical study in Australia and New Zealand have requested Ifenprodil for their personal use.
The patients are participating in a Phase 2 proof of concept study of NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis (IPF) and chronic cough.
Algernon is helping the clinical sites obtain additional drug supply through the Australian Government’s Special Access Scheme, a mechanism allowing patients to access unapproved therapeutic goods.
As previously stated, the company is projecting that top-line data from the Phase 2 study will be available in July 2022.
The company is advising that it is not making any express or implied claims that Ifenprodil has the ability to cure or treat IPF or chronic cough at this time.
Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets.
Algernon has filed intellectual property rights globally for Ifenprodil for the treatment of respiratory diseases.
Algernon Pharmaceuticals Inc. (AGN) opened trading at C$4.29.
